Trials / Not Yet Recruiting
Not Yet RecruitingNCT06684522
Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Northwestern University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Upadacitinib 15 MG | Upadacitinib 15mg daily |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2024-11-12
- Last updated
- 2024-11-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06684522. Inclusion in this directory is not an endorsement.